

Mortality Across Two ART Trials Enrolling at ≤200 verses ≤350 CD4 cells/uL in Kenya



Rachel Silverman.¹ Michael Chung.² James Kiarie.³ Nelly Yatich.² Julia Nioroge.² Catherine Kiptiness.² Samah Sakr.⁴ Grace John-Stewart.² and Lisa Frenkel⁵ ¹Epidemiology, University of Washington, Seattle, USA: ²Global Health, University of Washington, Seattle, USA: ³University of Nairobi, Kenva: ⁴Coptic Hospital, Nairobi, Kenva: ⁵Pediatrics, University of Washington, Seattle, WA, USA



Background

- In 2011, Kenvan HIV treatment guidelines changed from initiating ART at a CD4 of ≤200 to ≤350 cells/ul. Guidelines were changes again to initiating ART at ≤ 500 cells/ul in June of 2014.
- · We compared 6-month mortality in 2 research cohorts, one enrolled before and one after the 2011 ART initiation guidelines changed.
- Early mortality following HAART initiation may be unaffected by ARVs since early deaths are often caused by already advanced illness due to co-infection or to immune reconstitution syndrome.
- · We hypothesized that following the new guidelines to initiate HAART at higher CD4 counts, 6-month mortality following ART initiation would be lower in a cohort of patients initiating HAART in 2013 vs. 2006 for clinical trials

Methods

- · Study Population: HIV seropositive adults enrolled in 2 clinical trials at the Coptic Hope Center, in Nairobi Kenya with similar enrollment criteria.
 - 2006: Drug Adherence Intervention
 - 2013: Drug Resistance Testing Intervention
- · Inclusion Criteria: ART-naïve HIV seropositive adults enrolled in a clinical trial
- · Follow-up: Patients were followed during monthly visits for 18 months in 2006 and 15 months in 2013. Missed visits were investigated to determine if the participant had died or were unable/unwilling to participate using standardized procedures across both studies.
- Statistical Analysis
 - o Subjects who enrolled after Aug 4 2014 and those who withdrew or died prior to HAART initiation were omitted from the analysis.
 - · Subjects who were loss to follow-up were censored at the last time-point they were known to be alive. Subjects were administratively censored at 180 days if they had not died or were loss to follow-up prior to that time point.
 - A t-test was used to compare mean baseline CD4 between cohorts.
 - Cox proportional hazards regression was used to calculate hazard ratios (HR) comparing mortality between the study cohorts using time from enrollment to death within 6 months.

Acknowledgements

- · We thank the participants in the different studies and the health care team members at the Coptic Hope Center, Nairobi, Kenva
- These studies were supported by the National Institutes of Health (NIH)

Table 1. Participant baseline characteristics by study cohort

Variable§	2006 Adherence Study (N=400)	2013 Resistance Study (N=515)		
Age (years)*	37 (8); 36 (31, 42)	39 (10); 38 (33, 46)		
Female*	265 (66%)	228 (44%)		
Married or Attached	205 (51%)	273 (53%)		
Education (years)	11 (4); 11 (8, 13)	11 (4), 12 (8, 14)		
Unemployed*	129 (32%)	216 (42%)		
Flush toilet*	183 (46%)	311 (61%)		
# of persons living in house*	4 (2); 4 (2, 5)	4 (2); 3 (2, 5)		
Travel time to clinic (hours)*	0.93 (0.96); 0.67 (0.5, 1)	1.45 (2.41); 1 (0.67, 2)		
Age of sexual debut (years)*	18 (3); 18 (16, 20)	18 (3); 18 (16, 20)		
Lifetime sexual partners	6 (10); 4 (2, 7)	6 (20); 3 (2, 5)		
Ever exchange money for sex*	40 (10%)	29 (6%)		
CD4 count*	125 (82); 116 (61, 183)	194 (165); 180 (77, 280)		

[§]For continuous variables, the mean (standard deviation), and median (inter quartile range) are presented. For binary variables the N (%) are presented, *Indicates p-value <0.05. For continuous variables, a t-test assuming unequal variance was performed, and for binary variables, a chi2 test was performed, comparing the 2013 and 2006 cohorts.

Figure 1, Kaplan-Meier Survival Estimates: 6-Month Mortality by Cohort




Table 2. Frequency of death and loss or withdraw from study (LTFU) within 6 months by cohort and HAART initiation status

Status at	20	06 cohort (N=4	00)	2013 cohort (N=515)			
6 months	Initiators	Non-initiators	Total	Initiators	Non-initiators	Total	
TFU	13 (4%)	29 (76%)	42 (11%)	40 (8%)	17 (52%)	57 (11%)	
Death	18 (5%)	8 (21%)	26 (7%)	20 (4%)	14 (42%)	34 (7%)	
living	331 (91%)	1 (3%)	332 (83%)	422 (88%)	2 (6%)	424 (82%)	
Total	362 (100%)	38 (100%)	400 (100%)	482 (100%	33 (100%)	515 (100%)	

Results

Figure 2. Kaplan-Meier survival estimates: 6-month mortality by cohort and enrollment CD4 (all subjects with follow-up)




Table 3. Distribution of CD4 count and mortality by study cohort

	able 5. Distribution of CD4 count and mortality					y by stuu	by study conort Table 4. Upperd ratios (UD) for 6 month me			and a set by second at the little of
	CD4 Count	All Subjects			Mortality Incidence		Table 4. Hazard ratios (HR) for 6-month mortality			
(cells/ul)		2006		2013		2006	2013 Model Adjustme	Model Adjustments	2013 vs. 2006 hts HR (95% Cl); p-value	
	Category	N (%)	N (%) died	N (%)	N (%) died	N (%)	N (%)	(at baseline)	All subjects with FU time	HAART initiators
	<50	82 (21%)	10 (12%)	92 (18%)	16 (17%)	10 (2.5%)	16 (3.1%)	• •		
	50-99	92 (23%)	8 (9%)	58 (11%)	5 (9%)	8 (2%)	5 (1%)	Unadjusted	0.97 (0.58, 1.62); 0922	0.84 (0.44, 1.59); 0.593
		. ,		. ,	. ,	. ,	. ,	Age & Sex	0.99 (0.58, 1.68); 0.965	0.85 (0.44, 1.65); 0.634
	100-149	72 (18%)	4 (6%)	56 (11%)	5 (9%)	4 (1%)	5 (1%)	Time to Clinic	0.97 (0.58, 1.62); 0.910	0.86 (0.45, 1.65); 0.650
	150-199	83 (21%)	2 (2%)	70 (14%)	5 (7%)	2 (0.5%)	5 (1%)	Time to Chinic	0.97 (0.56, 1.62), 0.910	0.66 (0.45, 1.65), 0.650
	>200	69 (1%)	2 (3%)	237 (46%)	2 (1%)	2 (0.5%)	2 (0.4%)	Unemployed	0.96 (0.57, 1.59); 0.862	0.84 (0.44, 1.59); 0.596
		. ,		. ,	. ,	. ,	. ,	CD4 count	1.23 (0.73, 2.06); 0.440	1.11 (0.58, 2.13) 0.756
5	Missing CD4	2 (0.5%)	0 (0%)	2 (0.4%)	1 (50%)	0 (0%)	1 (0.2%)	ob i count	1120 (0110, 2100), 01110	1.11 (0.00, 2.10) 0.100
90	Total	400 (100%)	26 (7%)	515 (100%)	34 (7%)	400 (100%)	515 (100%)			
		,	(,	,,	,	,	,		0	

Model 2013 vs. 2006 **∆**diustments HR (95% CI); p-value (at baseline) All subjects with FU time HAART initiators

Inadjusted	0.97 (0.58, 1.62); 0922	0.84 (0.44, 1.59); 0.593
lge & Sex	0.99 (0.58, 1.68); 0.965	0.85 (0.44, 1.65); 0.634
ime to Clinic	0.97 (0.58, 1.62); 0.910	0.86 (0.45, 1.65); 0.650
Inemployed	0.96 (0.57, 1.59); 0.862	0.84 (0.44, 1.59); 0.596
D4 count	1.23 (0.73, 2.06); 0.440	1.11 (0.58, 2.13) 0.756

Conclusions

- With implementation of guidelines to initiate ART at a higher CD4 count (from ≤200 to ≤350 cells/uL). the mean CD4 count increased among those accessing care to initiate ART (125 cells/uL in 2006 vs. 194 cells/uL in 2013)
- Despite new guidelines, many participants initiated ART with dangerously low CD4 counts <50 cells/uL. Earlier HIV diagnosis and rapid linkage to care is necessary to achieve survival gains from new ART auidelines.

50	02 (2170)	10 (12/0)	32 (1070)	10 (17 /0)	10 (2.070)	10 (0.170)
0-99	92 (23%)	8 (9%)	58 (11%)	5 (9%)	8 (2%)	5 (1%)
00-149	72 (18%)	4 (6%)	56 (11%)	5 (9%)	4 (1%)	5 (1%)
50-199	83 (21%)	2 (2%)	70 (14%)	5 (7%)	2 (0.5%)	5 (1%)
200	69 (1%)	2 (3%)	237 (46%)	2 (1%)	2 (0.5%)	2 (0.4%)
lissing CD4	2 (0.5%)	0 (0%)	2 (0.4%)	1 (50%)	0 (0%)	1 (0.2%)
otal	400 (100%)	26 (7%)	515 (100%)	34 (7%)	400 (100%)	515 (100%)

Summary

- · Higher CD4 was associated with lower mortality within 6 months in both cohorts.
- More subjects enrolled with higher CD4 count in 2013.
- There was no statistically significant difference in mortality risk within 6 months between the cohorts. 2013 had lower 6 month mortality than 2006 among those who initiated HAART (not significant).
- 3% fewer subjects subjects enrolled with a CD4 count <50 cells/uL in 2013 (18%) than in 2006 (21%).
- Mortality within 6 months among those with CD4 <50cells/uL was greater in 2013 (17%) than 2006 (12%).